GNBT - Generex Enters $50 Billion Cannabis Pharmaceuticals Sector With Canopy Growth Backed Partner
October 31 2018 - 1:26PM
InvestorsHub NewsWire
New York, NY – October 31, 2018 – InvestorsHub NewsWire -- Generex
Biotechnology Corp (OTCQB: GNBT) today announced a deal with HydRx Farms Ltd. which is
more commonly known by its operating name, Scientus Pharma.
Scientus is backed by none other than Canopy Growth (NYSE:
CGC). Check out the bottom of page 5 of Canopy Growth’s Management
Discussion & Analysis found on Canopy’s website to see their
9.9% HydRx ownership. Generex, by itself is no slouch.
Generex, separate from Scientus and Canopy, has just filed an investigational new drug application
(IND) with the U.S. Food & Drug Administration (FDA) to
initiate Phase II Clinical Trials of a vaccine for patients
with breast cancer. The Generex breast cancer vaccine was
develop in conjunction with research conducted with Merck (NYSE:
MRK). Together Scientus and Generex plan to deliver Scientus’s
proprietary THC and CBD extractions via Generex’s RapdMist buccal
mucosa delivery technology. In other words, a medicinal THC
and CBD delivered a spray in your
mouth.
Generex is currently a quiet giant of a
pharmaceutical company that most people probably are not yet aware
even exists. Do a little research and you will find Generex
is loaded with proprietary, intellectual property protected
pharmaceutical technology. Given its recent FDA trials
announcement and today’s partnership with Scientus, Generex is
likely ready to no longer be quiet about its
gianthood.
Do a little more research and you will
find the Generex has a pending 20:1 dividend coming soon. With just over one
million shares currently issued and out, the dividend will take the
issued and out just over 21 million with the holders of the roughly
one million shares each getting 20 more shares for every share they
own on the ex-dividend date. And no, the ex-dividend date has
not yet been set, but looks to be coming
soon.
At a $10 million market capitalization,
given the market capitalization of GW Pharmaceuticals (GWPH) at $4
billion, not to mention the $100 million market capitalization of
delinquent filer Cannabis Science (OTC: CBIS), GNBT seems
extraordinarily undervalued. With GNBT’s IP portfolio, the
current less than $10 PPS deserves to at least hold post the 20:1
dividend giving an investment now a potential 2000% ROI. Even
if the PPS were to remain at its currentl level, that will still
just be a $200 million market capitalization. The GNBT market
cap likely has potential beyond $200 million giving a $10 per share
investment now even a more dramatic upside
opportunity.
Learn more about Generex at http://www.generex.com/
DISCLAIMER: NextBigTicker.com (NBT)is
a third party publisher and news dissemination service
provider. NBT is NOT affiliated in any manner with any company
mentioned herein. NBT is news dissemination solutions provider and
are NOT a registered broker/dealer/analyst/adviser, holds no
investment licenses and may NOT sell, offer to sell or offer to buy
any security. NBT's market updates, news alerts and corporate
profiles are NOT a solicitation or recommendation to buy, sell or
hold securities. The material in this release is intended to be
strictly informational and is NEVER to be construed or interpreted
as research material. All readers are strongly urged to perform
research and due diligence on their own and consult a licensed
financial professional before considering any level of investing in
stocks. All material included herein is republished content
and details which were previously disseminated by the companies
mentioned in this release or opinion of the writer. NBT is not
liable for any investment decisions by its readers or subscribers.
Investors are cautioned that they may lose all or a portion of
their investment when investing in stocks. NBT has not been
compensated for this release and HOLDS NO SHARES OF ANY
COMPANY NAMED IN THIS RELEASE.
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not
occur.
Source: www.nextbigticker.com